Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peter W. Ketch
Observed names:
Ketch, Peter,
P. Ketch,
Peter W. Ketch,
Peter Ketch
Institutions:
University of Alabama at Birmingham,
UAB Medicine
Observed institutions:
University of Tennessee Health Science Center,
University of Alabama at Birmingham,
UAB Medicine,
O'Neal Comprehensive Cancer Center
ORCID:
0000-0003-4770-1579
Observed ORCID:
0000-0003-4770-1579
OpenAlex ID:
A5095048451
Increased disparities associated with black women and abnormal cervical cancer screening follow-up
2022
·
Teresa K.L. Boitano
, Peter Ketch
, et al.
·
Gynecologic Oncology Reports
·
39
PDF
An Update on Human Papillomavirus Vaccination in the United States
2023
·
Teresa K.L. Boitano
, Peter W. Ketch
, et al.
·
Obstetrics and Gynecology
·
22
PDF
Same-day discharge after robotic surgery for endometrial cancer
2021
·
Naixin Zhang
, Ben Wilson
, et al.
·
Journal of Robotic Surgery
·
18
Pharmacotherapy for cervical cancer: current standard of care and new perspectives
2024
·
Peter W. Ketch
, Rennan S. Zaharias
, et al.
·
Expert Opinion on Pharmacotherapy
·
6
PDF
Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
2025
·
Peter W. Ketch
, Carly Bess Scalise
, et al.
·
JCO Precision Oncology
·
5
PDF
Direct oral anticoagulants (DOACs) for postoperative venous thromboembolism prophylaxis in patients with gynecologic malignancies: A quality mini-review
2024
·
Peter W. Ketch
, Sean C. Dowdy
, et al.
·
Gynecologic Oncology Reports
·
5
Progression to Severe Chronic Hypertension 5–7 Years After a Pregnancy With Mild Chronic Hypertension
2022
·
Ayamo Oben
, Jeff M. Szychowski
, et al.
·
Obstetrics and Gynecology
·
5
PDF
Supporting our survivors: an evaluation of the facilitators and barriers to advocacy in cervical and breast cancer survivors
2025
·
Lia Bos
, Elizabeth Pinto
, et al.
·
The Oncologist
·
2
PDF
Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer
2024
·
Peter Ketch
, Fernando Recio
, et al.
·
Gynecologic Oncology
·
2
Venous thromboembolism risk for patients with BMI ≥40 kg/m2 undergoing robotic surgery for endometrial cancer
2025
·
Kaitlyn G. Dinkins
, Grace M. Lee
, et al.
·
Gynecologic Oncology Reports
·
1
Frequency and outcomes of co-mutations according to ProMisE classifiers in endometrial cancer
2024
·
Rouba Ali-Fehmi
, Michael Toboni
, et al.
·
Gynecologic Oncology
·
1
A phase II study evaluating carboplatin/paclitaxel/pembrolizumab among newly diagnosed stage III/IV epithelial ovarian cancer patients receiving neoadjuvant chemotherapy followed by olaparib/pembrolizumab maintenance
2024
·
Kaitlyn Kincaid
, Peter Ketch
, et al.
·
Gynecologic Oncology
·
1
Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring among patients with advanced or recurrent endometrial cancer
2024
·
Michael Toboni
, Larry Maxwell
, et al.
·
Gynecologic Oncology
·
1
An Update on Human Papillomavirus Vaccination in the United States
2023
·
Teresa K. L. Boitano
, Peter W. Ketch
, et al.
·
Obstetrical & Gynecological Survey
·
1
Racial and ethnic disparities associated with abnormal cervical cancer screening follow-up (391)
2022
·
Teresa Boitano
, Peter Ketch
, et al.
·
Gynecologic Oncology
·
1
Novel Mechanism of Disease: Altered RNA metabolism due a dysfunctional RNA binding protein contributes to neurodegeneration in MS (P2.362)
2017
·
Michael Levin
, Sangmin Lee
, et al.
·
Neurology
·
1
A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib
2026
·
Carson C. Edwards
, Kati A. Turner
, et al.
·
Gynecologic Oncology
A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma
2026
·
Kati A. Turner
, Carson C. Edwards
, et al.
·
Gynecologic Oncology
A phase I open label, dose escalation clinical trial assessing the safety, tolerability, and feasibility of pNGVL4aCRTE6E7L2 HPV DNA vaccine administration via intramuscular TriGrid electroporation delivery system to patients with HPV16+ high-grade cervical intraepithelial neoplasia
2026
·
Dana Lewis
, Teresa Boitano
, et al.
·
Gynecologic Oncology
Phase I clinical trial assessing the safety and feasibility of intramuscular pNGVL4a-CRTE6E7L2 and TA-CIN administration for the treatment of patients with HPV16+ atypical squamous cells of unknown significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)
2026
·
Kati Turner
, Kimberly Levinson
, et al.
·
Gynecologic Oncology
Single-arm phase II study of carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy with advanced-stage ovarian, fallopian tube or primary peritoneal cancer who are folate receptor α positive
2026
·
Carson Edwards
, Kati Turner
, et al.
·
Gynecologic Oncology
Patient perspectives on primary HPV testing for cervical cancer screening
2026
·
Christopher Mayer
, Rivvi Crivelli
, et al.
·
Gynecologic Oncology
A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/paclitaxel/pembrolizumab in patients receiving neoadjuvant chemotherapy (NACT) followed by pembrolizumab maintenance with or without olaparib
2026
·
Carson Edwards
, Kati Turner
, et al.
·
Gynecologic Oncology
A phase Ib/II single arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma
2026
·
Kati Turner
, Carson Edwards
, et al.
·
Gynecologic Oncology
Physician Perspectives on the Transition to Primary Human Papillomavirus Testing for Cervical Cancer Screening
2026
·
Peter W. Ketch
, Teresa K.L. Boitano
, et al.
·
Journal of Lower Genital Tract Disease
Show more works
View as search
Works count:
47
Citation count:
111
H-index:
5
I10-index:
3
Year
Topic
Type